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Abstract
Background—In patients with chronic lymphoid leukemia (CLL) or small lymphocytic
lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are
associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of
Bruton’s tyrosine kinase, in patients at risk for a poor outcome.
Methods—In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients
with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody
ofatumumab. The primary end point was the duration of progression-free survival, with the
duration of overall survival and the overall response rate as secondary end points.
Results—At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free
survival; the median duration was not reached in the ibrutinib group (with a rate of progression-
free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab
group (hazard ratio for progression or death in the ibrutinib group, 0.22; P<0.001). Ibrutinib also
significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005). At 12 months, the
overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. The
overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group
(42.6% vs. 4.1%, P<0.001). An additional 20% of ibrutinib-treated patients had a partial response
with lymphocytosis. Similar effects were observed regardless of whether patients had a
chromosome 17p13.1 deletion or resistance to purine analogues. The most frequent
nonhematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group
and fatigue, infusion-related reactions, and cough in the ofatumumab group.
Conclusions—Ibrutinib, as compared with ofatumumab, significantly improved progression-
free survival, overall survival, and response rate among patients with previously treated CLL or
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SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number,
NCT01578707.)
Chronic lymphoid leukemia (CLL) is characterized by a variable natural history that is
partly predicted by clinical and genomic features.1 Therapy for CLL has evolved from
monotherapy with alkylating agents to chemoimmunotherapy. 2,3 Each of the combination
regimens has shown prolonged rates of progression- free survival, as compared with similar
regimens that do not contain antibodies.
Treatment of patients with relapsed CLL often includes regimens such as bendamustine and
rituximab,4 ofatumumab,5 or investigational agents.6–8 Ofatumumab was approved by the
Food and Drug Administration (FDA) and the European Medicines Agency on the basis of a
single-group study involving patients who had resistance to fludarabine and alemtuzumab
therapy; with an overall response rate of 58%,5 ofatumumab has been recommended in
international consensus guidelines as a therapeutic option for patients with previously
treated CLL.9,10
A short duration of response to initial therapy or adverse cytogenetic abnormalities have
been associated with a poor outcome among patients receiving conventional therapy.9,11,12
Identifying new therapies that prolong survival remains an important need for these patients.
Ibrutinib (Imbruvica, Pharmacyclics and Janssen) is a first-in-class, oral covalent inhibitor of
Bruton’s tyrosine kinase, an essential enzyme in B-cell receptor signaling, homing, and
adhesion. 13–15 On the basis of response rates in single-group, phase 2 studies, ibrutinib was
recognized by the FDA as a breakthrough therapy and was granted accelerated approval for
patients with mantle-cell lymphoma (in November 2013) and CLL (in February 2014) who
had received at least one previous therapy. Among patients with relapsed or refractory CLL
or small lymphocytic lymphoma (SLL), those who received ibrutinib had a response rate of
71%, according to investigator assessment, and a progression-free survival rate of 75% at 2
years.13 In this study, drug toxicity did not result in the discontinuation of ibrutinib in most
patients. On the basis of early results of the phase 2 trial, we initiated a multicenter, open-
label, randomized, phase 3 trial, the Study of Ibrutinib versus Ofatumumab in Patients with
Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE), to compare once-
daily oral ibrutinib with an active control single-agent therapy, ofatumumab, in patients with
relapsed or refractory CLL or SLL.
METHODS
PATIENTS
Patients with CLL or SLL requiring therapy16 were eligible for enrollment if they had
received at least one previous therapy and were considered to be inappropriate candidates
for purine analogue treatment because they had a short progression-free interval after
chemoimmunotherapy or because they had coexisting illnesses, an age of 70 years or more,
or a chromosome 17p13.1 deletion (Text S1 in the Supplementary Appendix, available with
the full text of this article at NEJM.org). Patients were required to have an Eastern
Cooperative Oncology Group (ECOG) performance status17 of less than 2 (on a scale from 0
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to 5, with higher scores indicating greater disability), an absolute neutrophil count of at least
750 cells per microliter, a platelet count of at least 30,000 cells per microliter, and adequate
liver and kidney function. Patients requiring warfarin or strong CYP3A4/5 inhibitors were
excluded. All patients provided written informed consent.
STUDY OVERSIGHT
The study was approved by the institutional review board or independent ethics committee
at each participating institution and was conducted in accordance with the provisions of the
Declaration of Helsinki and the International Conference on Harmonization Guidelines for
Good Clinical Practice. The study was sponsored by Pharmacyclics and Janssen. All the
authors and their research teams collected the data. Representatives of Pharmacyclics
designed the study, confirmed the accuracy of the data, and compiled the data for analysis;
Janssen representatives had no active role in the study. The authors had full access to the
data and analyses for the compilation of this report. The first author wrote the first draft of
the manuscript, which was reviewed, modified, and approved in its final version by all the
authors. Editorial assistance was provided by two professional medical editors funded by
Pharmacyclics. All the authors vouch for the accuracy and completeness of the data reported
and the fidelity of the study to the protocol (available at NEJM.org) and made the decision
to submit the manuscript for publication.
STUDY REVIEW
An independent review committee, whose members were unaware of study-group
assignments and lymphocyte counts, assessed progression and response. An independent
data and safety monitoring committee evaluated safety and reviewed data from the protocol-
specified interim analysis.
RANDOMIZATION AND TREATMENT
From June 2012 through April 2013, we enrolled 391 patients at 67 sites in the United
States, Australia, and seven European countries. Patients were randomly assigned to receive
either oral ibrutinib (at a dose of 420 mg once daily) until disease progression or the
occurrence of unacceptable toxic effects or intravenous ofatumumab for up to 24 weeks at
an initial dose of 300 mg at week 1, followed by a dose of 2000 mg weekly for 7 weeks and
then every 4 weeks for 16 weeks, consistent with local labeling. Patients were stratified
according to whether they had resistance to purine analogue chemoimmunotherapy (defined
as no response or a relapse within 12 months after the last dose of a purine analogue) and
whether they had a chromosome 17p13.1 deletion.
During this study, promising data from the phase 2 trial13 led investigators to request, and
the steering committee to recommend, crossover of patients in the ofatumumab group to the
ibrutinib group. This revision was supported by the data and safety monitoring committee
and was discussed with health authorities. Approximately 4 months after the last patient
underwent randomization, a protocol amendment allowed patients in the ofatumumab group
who had disease progression, as confirmed by an independent review committee, to receive
ibrutinib.
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STUDY END POINTS
The primary end point was the duration of progression- free survival, as assessed by the
independent review committee, according to the criteria of the International Workshop on
Chronic Lymphocytic Leukemia.11 (Details regarding criteria for a complete response,
partial response, stable disease, and progressive disease are provided in Table S1 in the
Supplementary Appendix.) On the basis of a clarification adopted in 2012, treatment-related
lymphocytosis was not considered to be progressive disease.11 Key secondary end points
included the duration of overall survival and the response rate. The criteria of the
International Workshop on Chronic Lymphocytic Leukemia require the use of computed
tomography (CT) to evaluate response and persistent improvement for at least 2 months to
confirm response.11
Patients were monitored weekly for the first 8 weeks, every 4 weeks until month 6, and then
every 12 weeks, with full response assessments performed every 12 weeks. Toxicity was
graded according to the criteria of the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0; the criteria of the International Workshop on
Chronic Lymphocytic Leukemia were used to evaluate hematologic toxicity. Reports of eye-
related adverse events were collected proactively on the basis of preclinical toxicology
studies in dogs that revealed corneal abnormalities in animals receiving ibrutinib at a dose of
150 mg per kilogram of body weight per day (equivalent dose in humans, 81 mg per
kilogram per day).18–20 Pathologists at a central laboratory assessed the results of interphase
fluorescence in situ hybridization (FISH) to evaluate cytogenetic factors (a procedure that
was also performed at local site laboratories), measurements of serum β2-microglobulin, and
mutational analysis of immunoglobulin heavy-chain variable (IGHV) genes. (The presence
of unmutated genes is usually associated with a poorer response to therapy and a worse
outcome.)
STATISTICAL ANALYSIS
The primary end point, progression-free survival, was used in the calculation of the study
sample size. The number of required events was based on a target hazard ratio for
progression or death of 0.60, as calculated with the use of a two-sided log-rank test at an
alpha level of 0.05, with a study power of at least 90%. The efficacy boundary (two-sided
P<0.028) was crossed at the preplanned interim analysis, and the results from that analysis
are presented in this report. The primary analysis was a two-sided log-rank test stratified
according to the presence or absence of the chromosome 17p13.1 deletion and the disease
refractory status at randomization. The type I error was controlled through adjustment of the
significance level with the use of the O’Brien–Fleming boundary21 for the interim analysis
and with the use of a hierarchical closed-testing procedure for primary and ordered
secondary end points.
RESULTS
PATIENTS
The baseline characteristics of the patients were generally well balanced between the two
study groups (Table 1, and Table S2 in the Supplementary Appendix). The majority of
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patients had advanced- stage disease. Patients in the ibrutinib group had undergone a median
of three previous therapies, and those in the ofatumumab group had undergone a median of
two previous therapies. The majority of patients had received previous treatment with purine
analogues, alkylating agents, and anti-CD20 antibodies, which were frequently administered
in combination. The percentage of patients with bulky disease (≥5 cm) was higher in the
ibrutinib group than in the ofatumumab group (64% vs. 52%). Approximately 57% of the
patients in the two study groups had a deletion at either chromosome 17p13.1 or
chromosome 11q22.3. The median follow-up time was 9.4 months (range, 0.1 to 16.6), and
86% of patients were still receiving ibrutinib at the time of this analysis (Fig. S1 in the
Supplementary Appendix).
EFFICACY
Progression-free Survival—Ibrutinib significantly prolonged the duration of
progression-free survival, with the median not reached at a median follow-up of 9.4 months,
as compared with a median duration of progression-free survival of 8.1 months with
ofatumumab. The hazard ratio for progression or death in the ibrutinib group was 0.22 (95%
confidence interval [CI], 0.15 to 0.32; P<0.001) (Fig. 1A). This represents a 78% reduction
in the risk of progression or death among patients treated with ibrutinib, as compared with
ofatumumab. At 6 months, 88% of patients in the ibrutinib group were still alive with no
disease progression, as compared with 65% in the ofatumumab group. The effect of ibrutinib
on progression-free survival was observed regardless of baseline clinical characteristics or
molecular features (Fig. 2).
Among patients with a chromosome 17p13.1 deletion, the median duration of progression-
free survival was not reached in the ibrutinib group, as compared with a median of 5.8
months in the ofatumumab group (hazard ratio for progression or death, 0.25; 95% CI, 0.14
to 0.45). At 6 months, 83% of the patients with this deletion in the ibrutinib group, as
compared with 49% of those with this deletion in the ofatumumab group, were alive with no
disease progression. Richter’s transformation (CLL that has evolved into an aggressive,
rapidly growing large-cell lymphoma) was confirmed in two patients in each study group.
Prolymphocytic leukemia developed in an additional patient in the ibrutinib group.
Overall Survival—Ibrutinib, as compared with ofatumumab, significantly prolonged the
rate of overall survival (hazard ratio for death in the ibrutinib group, 0.43; 95% CI, 0.24 to
0.79; P = 0.005), with the risk of death reduced by 57% (Fig. 1B). At 12 months, the overall
survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. At the time
of this analysis, 57 patients in the ofatumumab group had crossed over to receive ibrutinib
after confirmed disease progression. The survival effect was based on an analysis in which
data were censored at the time of crossover. At 12 months, the survival effect was also
observed in the uncensored sensitivity analysis (hazard ratio for death, 0.39; P = 0.001), with
an overall survival rate of 90% in the ibrutinib group and 79% in the ofatumumab group
(Fig. S2 in the Supplementary Appendix). The difference in overall survival supporting the
superiority of ibrutinib was preserved in all the subgroups defined according to pretreatment
and genetic features (Fig. S3 in the Supplementary Appendix).
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Response—The independently assessed response rate was significantly higher in the
ibrutinib group than in the ofatumumab group (Fig. 3A). Overall, 43% of the patients in the
ibrutinib group had a partial response, as compared with 4% in the ofatumumab group (odds
ratio, 17.4; 95% CI, 8.1 to 37.3; P<0.001). In addition, 20% of the patients receiving
ibrutinib had a partial response with lymphocytosis (resulting in a 63% response rate).
Lymphocytosis was observed in 69% of the patients who were treated with ibrutinib and
was not considered to be disease progression.11 The condition resolved in 77% of these
patients during follow-up. In a recent study, patients with a partial response with
lymphocytosis had rates of progression-free survival that were similar to those in patients
with a partial response.22 Investigator- assessed response rates were higher than
independently assessed response rates in the two study groups (Fig. 3B).
SAFETY
Treatment exposure was longer among patients receiving ibrutinib than among those
receiving ofatumumab (median duration, 8.6 months [range, 0.2 to 16.1] vs. 5.3 months
[range, 0 to 7.4]). The profiles of cumulative adverse events that occurred in at least 10% of
the patients are presented without adjustment for duration of exposure in Table 2. The most
frequent nonhematologic adverse events that occurred in at least 20% of the patients were
diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related
reactions, and cough in the ofatumumab group. Overall, 57% of the patients in the ibrutinib
group and 47% of the patients in the ofatumumab group had at least one adverse event of
grade 3 or higher. Serious adverse events are summarized in Table S3 in the Supplementary
Appendix. Adverse events of grade 3 or higher that occurred more frequently in the ibrutinib
group than in the ofatumumab group included diarrhea (4% vs. 2%) and atrial fibrillation
(3% vs. 0%); the latter event required cessation of therapy in one patient. An additional four
patients in the ibrutinib group and one patient in the ofatumumab group had grade 1 or 2
atrial fibrillation. Bleeding-related adverse events of any grade (most commonly, petechiae,
and including ecchymoses) were more common in the ibrutinib group than in the
ofatumumab group (44% vs. 12%). Major hemorrhage (any hemorrhagic event of grade 3 or
higher or resulting in transfusion of red cells or in hospitalization) was reported in two
patients (1%) in the ibrutinib group (including one patient with a subdural hematoma) and
three patients (2%) in the ofatumumab group.
Other adverse events that were more commonly noted among patients receiving ibrutinib
than among those receiving ofatumumab included rash (8% vs. 4%), pyrexia (24% vs. 15%),
and blurred vision (10% vs. 3%); all these events were generally grade 1 or 2 in severity.
The incidence of cataracts was 3% and 1%, respectively. Infections of any grade were more
common in the ibrutinib group (70% vs. 54%), whereas the frequency of infections of grade
3 or higher was similar in the two study groups (24% vs. 22%) (Table S4 in the
Supplementary Appendix). Infusion reactions, peripheral sensory neuropathy, urticaria,
night sweats, and pruritus were more common in the ofatumumab group. Basal-cell and
squamous-cell carcinomas were reported in 4% of the patients in the ibrutinib group and in
2% in the ofatumumab group; nonskin cancers were seen in 3% and 1% of the patients,
respectively.
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Discontinuation of treatment because of adverse events occurred in 4% of the patients in
each study group. Fatal events occurred in 4% of the patients in the ibrutinib group and in
5% of those in the ofatumumab group (Table S5 in the Supplementary Appendix). These
events were most commonly infectious in nature. Adverse events resulting in dose
reductions occurred in 4% of the patients treated with ibrutinib, with only diarrhea (which
occurred in three patients) leading to a dose reduction in more than one patient. Changes in
creatinine levels from baseline were similar in the two study groups, with a decrease in
creatinine clearance of any grade observed in 16% of the patients in the ibrutinib group and
in 17% of those in the ofatumumab group.
DISCUSSION
Among patients with relapsed CLL or SLL, including those who had a short duration of
response to prior therapy or who had adverse cytogenetic abnormalities, ibrutinib was
superior to ofatumumab with respect to progression-free survival, overall survival, and
response rate at a median follow-up of 9.4 months. The positive effect of ibrutinib was
observed in subgroups of patients with a high-risk chromosome 17p13.1 deletion and with
resistance to previous purine analogue therapy. Similar benefits with respect to progression-
free survival were observed regardless of age, clinical stage, and factors such as status with
respect to mutations in IGHV. The effect of ibrutinib on overall survival was significant, an
effect that was robust despite the crossover of 57 patients to the ibrutinib group after they
had disease progression while receiving ofatumumab; this effect was also observed in
subgroup and sensitivity analyses.
Except for a few differences, our findings are largely similar to those of other trials of
ibrutinib or ofatumumab. In each of the two groups in our study, the response rate as
determined by independent assessors was lower than the response rate as determined by
investigators. In the phase 2 study of ibrutinib monotherapy,13 in which response was
assessed by investigators, the response rate was 71%, which is similar to the 70% response
rate assessed by investigators in our study. The independently assessed response rate in the
ofatumumab group in our study appears to be lower than that in the pivotal study that was
based on 1996 National Cancer Institute guidelines for CLL,23 which did not require CT
scanning to confirm response.24 This difference may be due in part to the requirement in our
study for serial CT scanning, which was performed every 12 weeks, to confirm response.
Another ofatumumab study that compared response assessment between patients who
underwent CT scanning and those who did not undergo CT scanning showed substantial
differences in the rates of response between the two subgroups, with lower response rates
seen in the group that underwent CT scanning.25 Furthermore, the investigator-assessed
response rate among patients in the ofatumumab group in our study (21%) was similar to the
rate (23%) in a recent study that used 2008 criteria of the International Workshop on
Chronic Lymphocytic Leukemia.26 Reassuringly, the results with respect to progression-free
survival in the ofatumumab group in our study (median, 8.1 months) are similar to those in
historical reports (median, approximately 6 months).5
Previous reports of ofatumumab therapy showed that patients with refractory CLL had a
median survival of 12 months26 and 15 months,5 with no plateau in deaths. With a median
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follow- up of 9.4 months in our study, an early separation in the curves for overall survival
favored ibrutinib; however, the median was not reached in either study group. At later time
points, the survival curve for ofatumumab began to flatten, which may in part be a reflection
of the influence of ibrutinib on patients in the ofatumumab group who crossed over to
ibrutinib therapy.
Ibrutinib was associated with toxic effects that were expected on the basis of the results of
phase 2 studies. It appears that the drug can be safely administered even in a heavily
pretreated and elderly population with baseline coexisting conditions, such as the one in our
study. In the ibrutinib group, 32% of the patients had a decreased creatinine clearance, 64%
had cytopenias, and 32% had a score on the Cumulative Illness Rating Scale of more than 6
(ranging from 0 to 52, with higher scores indicating worse health status). Toxic effects did
not result in frequent dose reductions or treatment discontinuations.
One strength of a randomized, controlled trial is that background disease-related
complications may be differentiated from a treatment effect with a new agent. However, it is
important to note that patients in the ibrutinib group had a reporting period for adverse
events that was more than 3 months longer than that in the ofatumumab group (median
duration, 8.6 months vs. 5.3 months), and no exposure-adjusted analysis of adverse events
was performed.
The frequencies of renal complications and increased creatinine levels were similar in the
two study groups. Although the overall rate of infections was higher in the ibrutinib group,
the frequency of infections of grade 3 or higher did not differ significantly between the two
groups. Ocular symptoms were collected proactively and were reported more frequently
among patients in the ibrutinib group, including a small proportion of patients who reported
blurred vision. The development of cataracts in 3% of the patients receiving ibrutinib (as
compared with 1% in the control group) bears noting, since longer exposure may be
associated with an increased risk.
Atrial fibrillation of any grade was noted in 10 patients in the ibrutinib group, as compared
with 1 patient in the ofatumumab group, and led to the discontinuation of ibrutinib in 1
patient. Potential reasons for the higher rate of atrial fibrillation among patients receiving
ibrutinib are being explored. In clinical studies in which serial electrocardiographic studies
were performed, no evidence of arrhythmias was observed among patients receiving
ibrutinib.13,27
An adverse event of interest with ibrutinib from early studies was major hemorrhage,
including subdural hematoma. In our study, we excluded patients requiring warfarin but not
those requiring other forms of anticoagulation. The rate of major hemorrhage was similar in
the two study groups, with one subdural hematoma noted in a patient receiving ibrutinib.
Although mild bleeding episodes were more common in the ibrutinib group, adherence to
appropriate drug-withholding guidelines perioperatively and precautions regarding the use
of antiplatelet agents and anticoagulants resulted in no unexpected major bleeding
complications in the ibrutinib group. Further studies of the mechanism of bleeding,
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including bruising, that was observed among patients receiving ibrutinib have been
conducted28 or are planned.
In conclusion, ibrutinib was superior to ofatumumab in difficult-to-treat patients with
relapsed or refractory CLL or SLL, as measured by progression-free survival, overall
survival, and response. The improvement was observed across all subgroups that were
examined, including patients who were resistant to chemoimmunotherapy and those with a
chromosome 17p13.1 deletion, which confirms single-agent ibrutinib as an effective therapy
for CLL or SLL. Phase 3 studies examining the effect of ibrutinib in previously untreated
patients with CLL or SLL are ongoing (ClinicalTrials.gov numbers, NCT02048813 and
NCT01722487).
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Figure 1. Progression-free and Overall Survival
The durations of progression-free survival (Panel A) and overall survival (Panel B) were
significantly longer in the ibrutinib group than in the ofatumumab group. At a median
follow-up of 9.4 months, the median duration of progression-free survival was not reached
in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as
compared with a median of 8.1 months in the ofatumumab group; the median duration of
overall survival was not reached in either study group.
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Figure 2. Subgroup Analyses of Progression-free Survival
Shown are forest plots of hazard ratios for death or disease progression among subgroups of
patients in the ibrutinib group and the ofatumumab group. The size of the circle is
proportional to the size of the subgroup. The dashed vertical line indicates the overall
treatment effect for all patients. The only test for heterogeneity that was significant was for
geographic region (P = 0.02), although the treatment effect remained significant within each
region (P<0.001). The Rai staging system ranges from 0 (low risk) to I or II (intermediate
risk) to III or IV (high risk). The Eastern Cooperative Oncology Group (ECOG) score
ranges from 0 to 5, with higher scores indicating greater disability. Race was self-reported.
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Figure 3. Best Response to Therapy, as Assessed by Independent Reviewers and by Investigators
Shown are rates of patients’ best response to therapy, according to independent assessment
(Panel A) and investigator assessment (Panel B) with respect to complete response (CR),
complete response with incomplete hematopoietic recovery (CRi), partial response (PR),
partial response with lymphocytosis (PR+L), stable disease (SD), and progressive disease
(PD). Data were unknown, missing, or could not be evaluated for 5 patients in the ibrutinib
group in both the independent assessment and the investigator assessment and for 15
patients in the ofatumumab group in the independent assessment and 17 patients in the
group in the investigator assessment.
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Table 1
Characteristics of the Patients at Baseline. *
Characteristic Ibrutinib (N = 195) Ofatumumab (N = 196)
Patients with small lymphocytic lymphoma — no. (%) 10 (5) 8 (4)
Median age (range) — yr 67 (30–86) 67 (37–88)
Male sex — no. (%) 129 (66) 137 (70)
Cumulative Illness Rating Scale score >6 — no. (%)† 38 (32) 39 (32)
Creatinine clearance <60 ml/min — no. (%) 62 (32) 61 (31)
Median hemoglobin (range) — g/dl 11 (7–16) 11 (6–16)
Median platelet count (range) — per mm3 116,500 (20,000–441,000) 122,000 (23,000–345,000)
Median lymphocyte count (range) — per mm3 29,470 (90–467,700) 29,930 (290–551,030)
ECOG performance status — no. (%)‡
 0 79 (41) 80 (41)
 1 116 (59) 116 (59)
Bulky disease ≥5 cm — no. (%)§ 124 (64) 101 (52)
Interphase cytogenetic abnormalities — no. (%)
 Chromosome 11q22.3 deletion 63 (32) 59 (30)
 Chromosome 17p13.1 deletion ¶ 63 (32) 64 (33)
β2-microglobulin >3.5 mg/liter — no. (%) 153 (78) 145 (74)
Previous therapies
 Median no. (range) 3 (1–12) 2 (1–13)
 ≥3 — no. (%) 103 (53) 90 (46)
 Type of therapy — no. (%)
  Alkylator 181 (93) 173 (88)
  Bendamustine 84 (43) 73 (37)
  Purine analogue 166 (85) 151 (77)
  Anti-CD20 183 (94) 176 (90)
  Alemtuzumab 40 (21) 33 (17)
  Allogeneic transplantation 3 (2) 1 (1)
Median time from last therapy (range) — mo 8 (1–140) 12 (0–184)
Resistance to purine analogues — no. (%)|| 87 (45) 88 (45)
*
There were no significant differences between the two groups at baseline, except with respect to the presence of bulky disease of 5 cm or more (P
= 0.04) and the median time from last therapy (P = 0.02).
†Scores on the Cumulative Illness Rating Scale range from 0 to 52, with higher scores indicating worse health status. Scores on this test were
required only for patients 65 years of age or older, and coexisting illnesses were not included in the scoring.
‡Scores on the Eastern Cooperative Oncology Group (ECOG) performance status range from 0 to 5, with higher scores indicating greater
disability.
§
Measurement was based on the largest diameter of the longest lymph node at screening, according to the assessment of the independent review
committee.
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¶
Patients were stratified at randomization according to the presence or absence of this genetic abnormality.
||
Resistance was defined as no response or a relapse within 12 months after the last dose of a CD20-based chemoimmunotherapy regimen that
included a purine analogue.
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